Quarterly ResultApr 30, 2026, 04:03 PM
PCRX Q1 Revenue +5% to $177.4M; GAAP EPS $0.07; ZILRETTA Phase 3 Enrollment
AI Summary
Pacira BioSciences reported Q1 2026 total revenue of $177.4 million, a 5% increase year-over-year, driven by growth across its commercial portfolio, including EXPAREL volume growth of 7%. GAAP net income was $2.9 million ($0.07 per share), while non-GAAP net income was $24.5 million ($0.60 per share). The company completed enrollment in its Phase 3 registrational study for ZILRETTA in shoulder osteoarthritis, with topline results expected by year-end. Pacira also repurchased $50.0 million of common stock and reiterated its full-year 2026 financial guidance.
Key Highlights
- Completed enrollment in Phase 3 registrational study of ZILRETTA in shoulder osteoarthritis.
- Total revenue increased 5% to $177.4 million in Q1 2026.
- GAAP net income was $2.9 million, or $0.07 per share.
- Non-GAAP net income was $24.5 million, or $0.60 per share.
- EXPAREL net product sales grew 5% to $143.3 million.
- ZILRETTA net product sales increased 15% to $26.8 million.
- Repurchased 2.2 million shares for $50.0 million in Q1 2026.
- Reiterated full-year 2026 total revenue guidance of $745M to $770M.